BioPharma Resources

Drug Trial Radar · NCT07007312

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,300

Planned (sponsor's estimate)

Start

Sep 26, 2025

Primary completion

Nov 2031

Study completion Nov 2031

Sponsor

Lead sponsor
Kura Oncology, Inc.Industry
Sponsor type
Industry
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the SOC therapies venetoclax (ven) and azacitidine (aza), plus either ziftomenib or a placebo. In the second study, the Intensive Therapy Study, medically fit patients will receive (a) the SOC therapies cytarabine and daunorubicin, plus either ziftomenib or a placebo during a first treatment phase called induction, (b) cytarabine plus either ziftomenib or a placebo during a second treatment phase called consolidation, and (c) ziftomenib or a placebo during a third treatment phase called maintenance. The physician will determine which study is the appropriate treatment for the patient, but neither the patient nor their physician will know whether the patient has been assigned to receive ziftomenib or a placebo. This design is called "double-blinded".

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • ZiftomenibDrug

    Oral administration

  • PlaceboDrug

    Oral administration

  • VenetoclaxDrug

    Oral administration

  • Azacitidine (AZA)Drug

    Intravenous or subcutaneous administration

  • DaunorubicinDrug

    Intravenous administration

  • Cytarabine (Ara-C)Drug

    Intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS)Time frame: Defined as the time from randomization to date of death from any cause, assessed up to 36 months after last patient inclusion
  2. Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR)Time frame: Assessed up to 36 months after last patient inclusion
  3. Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS)Time frame: Defined as the time from randomization to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 36 months after last patient inclusion
  4. Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patientsTime frame: Assessed up to 36 months after last patient inclusion

Locations

141 sites in 17 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • University of California, Fresno

    Clovis, California · Recruiting

  • University of California, San Diego

    La Jolla, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • USC Norris Cancer Center

    Los Angeles, California · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • University of California, Irvine

    Orange, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Hartford HealthCare Cancer Institute

    Hartford, Connecticut · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Moffitt Cancer Center & Research Institute

    Tampa, Florida · Recruiting

  • Northwestern

    Chicago, Illinois · Not yet recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Kansas

    Fairway, Kansas · Recruiting

  • University of Kentucky

    Lexington, Kentucky · Recruiting

  • MGH

    Boston, Massachusetts · Recruiting

  • University of Massachusetts

    Worcester, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Wayne State University School of Medicine

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • HealthPartners Cancer Center at Regions Hospital (MN)

    Saint Paul, Minnesota · Recruiting

  • Rutgers Biomedical and Health Sciences

    New Brunswick, New Jersey · Recruiting

  • University of New Mexico

    Albuquerque, New Mexico · Recruiting

  • State University of New York at Buffalo

    Buffalo, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • Weill Cornell Medical Center

    New York, New York · Recruiting

  • University of North Carolina, Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Willamette Valley Cancer Institute

    Eugene, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Baptist Clinical Research Institute

    Memphis, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • TriStar Centennial Medical Center

    Nashville, Tennessee · Recruiting

  • Texas Oncology-Austin Midtown

    Austin, Texas · Recruiting

  • Texas Oncology-Presbyterian Cancer Center

    Dallas, Texas · Recruiting

  • University of Texas

    Houston, Texas · Recruiting

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.